OpenEvidence reached a 12 billion valuation following a 250 million Series D, hitting a 100 million...
The AMW Read
OpenEvidence's $12B valuation and hyper-growth in clinical decision-making represents a new top-tier entrant in Vertical AI (Healthcare) and validates the bypass of traditional hospital IT procurement.
NoveltySignificance
Healthcare & Bio Β· Player MapCapital Cycles
OpenEvidence reached a 12 billion valuation following a 250 million Series D, hitting a 100 million revenue run rate in under 12 months. With 430,000 clinicians generating 20 million monthly conversations, the platform bypasses slow hospital IT through direct adoption. By monetizing inference latency with targeted pharma ads, it creates a high-efficiency engine at the point of care. This signals a systemic shift where AI becomes the primary layer for clinical decision-making. π
